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Vancomycm redistribution: Dosing recommendations following high-
flux hemodialysis. Although increased vancomycin clearance has been
reported with highly permeable hemodialysis membranes (such as
polysulfone), failure to consider post-dialysis redistribution could lead
to unnecessary dosage supplementation. In protocol 1, twelve hemodi-
alysis patients admitted for vascular access thrombectomy received 15
mg/kg of vancomycin as surgical prophylaxis. Post-operatively, pa-
tients underwent high-flux hemodialysis (HFHD) for two hours using a
Fresenius" F-80 polysulfone dialyzer (QB = 417 49, Q = 800
ml/min). Vancomycin's intradialytic clearance increased 13-fold com-
pared to the patient's endogenous clearance (120 59vs. 9 8 mI/nun,
respectively) yet dialysate recovery indicated that only 17% of body
stores were removed (179 70 mg). Although serum vancomycin levels
decreased 33% during HFHD, vancomycin levels increased in all
patients following dialysis and the post-rebound values reached 87% of
the pre-dialysis concentration. In protocol 2, eight outpatients receiving
maintenance HFHD with a F-80 dialyzer (KtJV = 1.29 0.08) were
given 20 mg/kg of vancomycin immediately following dialysis on
Monday; pre- and post-levels were measured during the next three
dialysis treatments. The predialysis serum vancomycin levels were
>7.5 g/m1 (9.7 1.0 sg/ml; range 8.0 to 11.0) in all patients the
following Monday. Thus, vancomycin clearance is increased during
HFHD, but redistribution post-HD minimizes changes in serum levels.
We recommend a 20 mg/kg i.v. loading dose and subsequent doses of 15
mg/kg every seven days; to account for individual variability, weekly
vancomycin levels should be drawn before dialysis.
The availability of highly permeable dialysis membranes
(such as polysulfone) and "high-flux" hemodialysis (HFHD)
has fundamentally altered dialytic therapy in the 1990's. Unfor-
tunately, little information is available regarding the clearance
of commonly prescribed medications during HFHD, but recent
reports suggest that dosing recommendations based on conven-
tional dialyzers may not be applicable [1—3].
Vancomycin clearance by cuprophane or cellulose acetate
dialysis membranes is very limited [4—8]. In contrast, several
investigators have found that vancomycin clearance is in-
creased with the newer, highly-permeable dialyzers [1—3], and
suggested that a post-dialysis supplement be given [1, 2]. The 25
to 50% decline in serum vancomycin concentrations noted with
these more permeable dialyzers would seem to support this
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recommendation [1—3]. However, a "rebound" in serum con-
centrations following hemodialysis has been reported with a
number of drugs [9—13], suggesting that dosing decisions based
on measurements obtained immediately after dialysis may be
invalid. Two questions remain unresolved: does vancomycin
redistribute from tissue to plasma following HFHD, and if so,
what clinical impact does this have on dosage recommendations
and drug monitoring? Therefore, the objectives of this study
were to: (1) evaluate the extent of vancomycin removal during
HFHD, (2) determine if vancomycin redistribution occurs fol-
lowing HFHD, and (3) provide guidelines for dosage supple-
mentation and drug monitoring following HFHD.
Methods
Inpatient protocol (protocol 1)
To evaluate the extent of vancomycin removal by HFHD,
and whether vancomycin redistribution occurs following
HFHD, twelve patients (6 males, 6 females; mean age 50.2
13.1 years) admitted to Emory University Hospital for surgical
thrombectomy of their vascular access were enrolled. After
obtaining informed consent, a single intravenous dose of van-
comycin (15 mg/kg) was infused over one hour as antibiotic
prophylaxis on the afternoon or evening prior to the day
vascular access surgery was scheduled. Following surgery,
patients underwent a hemodialysis treatment and were usually
observed overnight and discharged the following day. The
average interval between vancomycin infusion and initiation of
hemodialysis was 24 hours (range 12 to 37 hours). Patients were
dialyzed using a FreseniusM 2008D or Kobe" Century 2 RO
hemodialysis machine, equipped with a FreseniusT" polysulfone
F-80 dialyzer (surface area = 1.9 m2) and received a two-hour
treatment (131 11 mm) with dialysate (bicarbonate) flow (QD)
maintained at 800 ml/min and the blood flow rate (QB) targeted
at 400 mI/mm.
Blood samples for measurement of serum vancomycin con-
centrations were collected as follows: (1) pre-dialysis samples
were drawn; before administering vancomycin, three hours
following completion of the infusion, pre-operatively, and just
prior to initiating hemodialysis; (2) intra-dialytic samples were
obtained from the arterial port every 30 minutes with the final
sample collected just prior to discontinuing dialysis (a total of 4
samples); (3) post-dialysis samples were obtained; immediately
after completion of dialysis, and then 0.5, 1.0, 1.5, 2, 4, 6, 12,
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24, 36 and 48 hours later. In three patients, post-dialysis blood
samples were not available due to inability to maintain penph-
era! venous access. The blood samples were collected in
non-heparinized tubes and the serum stored at —70°C prior to
analysis.
In the first four patients, aliquots of dialysate were collected
simultaneously with the timed blood samples, and the amount
of vancomycin removed during HFHD calculated from the
serial dialysate vancomycin concentrations and the dialysate
flow rate. For the eight remaining subjects, all expended
dialysate was collected in five gallon containers, and the total
volume calculated from weight and specific gravity (the CV was
4% when compared to the volume of dialysate measured
directly). Ten ml aliquots were saved from each container and
stored at —70°C prior to analysis.
Outpatient protocol (protocol 2)
To provide guidelines for dosage supplementation during
HFHD, 20 mg/kg of vancomycin was administered following a
Monday's dialysis session and pre- and post-dialysis vancomy-
cm levels measured during the following three dialysis treat-
ments. Participants were receiving maintenance HFHD using a
Fresenius°' P80 dialyzer and 2008D hemodialysis machine
using bicarbonate dialysate (QD = 800 mllmin). Hemodialysis
therapy was prescribed as dictated by their dialysis center
physician and the patients KtIV was used to estimate the
delivered dose of dialysis, where K is the urea clearance, t is the
duration of dialysis, and V is the volume of distribution of urea
[14]. At our dialysis unit >85% of the patients are dialyzed
using a F-80 dialyzer and the delivered Kt/V is 1.27 0.20
(mean SD) [15].
Eligibility criteria included: (1) end-stage renal disease
(ESRD) for 2 years and the absence of residual renal function;
(2) compliance with dialysis therapy as demonstrated by atten-
dance at >95% of treatments during the preceding seven
months; (3) no known allergy to vancomycin; (4) no acute
illness or vancomycin therapy within three weeks prior to the
study; and (5) absence of graft stenosis or thrombosis within
two months.
Eight patients (7 males, 1 female; mean age: 51 11 years,
range; 35 to 65 years) consented to participate. The study
protocol began on Monday and entailed four consecutive
HFHD treatments over seven days, corresponding to treat-
ments on Monday, Wednesday, Friday and Monday. Prior to
the first dialysis treatment, a baseline serum vancomycin level
was obtained from the venous line. Immediately following
dialysis, patients were weighed and then received 20 mg/kg of
vancomycin (in 250 ml of 5% dextrose in water) over 1 hour.
The duration of the infusion was recorded and the volume of the
intravenous tubing measured to determine the actual dose of
vancomycin administered. For each dialysis treatment we re-
corded: (1) the duration of the dialysis treatment; (2) pre- and
post-dialysis body weight; (3) blood and dialysate flow rates;
and (4) the time at which vancomycin levels were drawn. The
study protocols were approved by the Human Investigations
Committee of Emory University and all participants gave their
informed consent.
Vancomycin analysis
Vancomycin concentrations in serum and dialysate were
measured by HPLC using a Waters system containing a Nova-
pak Cl8 radial compression column maintained at 40°C in a
column oven, and LambdaMax Model 481 UV detector (210
nm) (Waters Associates, Milford, Massachusetts, USA), con-
nected to a Shimadzu C-R6A integrator (Shimadzu Corpora-
tion, Kyoto, Japan). After washing the C8 solid phase extrac-
tion column (Clean-UpTM; World Wide Monitoring, Horsham,
Pennsylvania, USA) three times with methanol and once with
deionized water, 500 p1 of plasma or 5 ml of dialysate were
applied. Vancomycin was then eluted from the C8 column with
1 ml of acidified methanol (20 p1 of concentrated HCL added to
100 ml HPLC grade methanol). Twenty p1 of the eluate was
then injected into the HPLC system and assayed using a mobile
phase of 8.5% acetonitrile in 20 m potassium phosphate (pH
3.5), and a flow rate of 1.5 mllmin.
Standards for serum or dialysate were made by adding known
concentrations of vancomycin to drug-free serum or normal
saline, respectively. The standard curves were linear from 5 to
60 g/ml (r2 = 0.99) using either vehicle, with an average
recovery of 98.0%; the CV's on duplicate samples varied from
2.7 to 4.9%.
Pharmacokinetic evaluations
The pharmacokinetic parameters were calculated using stan-
dard equations [16], modified to account for the contribution of
dialytic clearance [17]:
VDJEA = DOSe/AUCT x Ke
CLE = Dose/AUCT
CLD = RJAUCD
CLT = CLE + CL
(Eq 1)
(Eq 2)
(Eq 3)
(Eq 4)
Where VDEA is the volume of distribution, Dose is the
dose of vancomycin administered, AUCT is the total area under
the curve for all vancomycin concentration-time points extrap-
olated to infinity, Ke the endogenous elimination rate constant
obtained from the post-dialysis log-linear decline in serum
vancomycin concentrations following redistribution, CLE the
patient's endogenous clearance (interdialytic clearance), CL
the dialysis clearance (intradialytic clearance), CLT the appar-
ent total body clearance during dialysis, R the dialysate recov-
ery, or the total amount of drug recovered in the expended
dialysate, and AUCD is the area under the vancomycin concen-
tration-time curve during dialysis. Vancomycin body stores
available at the initiation of HFHD were calculated by multi-
plying the pre-dialysis vancomycin level times VDEA.
To determine whether vancomycin redistribution occurs fol-
lowing HFHD (protocol 1), serial serum vancomycin concen-
trations were measured for up to 48 hours following hemodial-
ysis. These results are expressed as: (1) time to maximum
rebound = the time interval between the immediate post-
dialysis level and the highest concentration attained during the
post-dialysis sampling phase; (2) percent rebound = [(B — A/A)
x 100%], where A = immediate post-dialysis level and B =
maximum post-dialysis concentration.
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Table 1. Selected pharmacokinetic parameters for patients receiving vancomycin and high-flux hemodialysis
Patient
no.
Weight
kg
VDAREA
liter/kg
CL CLE
mI/mm
Dialysate
recovery
mg
%
Rebound
Maximum
rebound
hr
1 56.8 1.5 296,4 6.7 340 48.5 12.0
2 69.1 1.0 118.7 6.4 196 60.5 4.0
3 75.0 NAA 121.4 NA 255 NA NA
4 99.4 1.5 104.6 1.2 158 35.7 1.0
5 65.2 1.3 117.5 2.7 181 37,7 4.0
6 66.2 0.6 135.5 3.6 185 23.9 6.0
7 50.5 NA 109.4 NA 220 NA NA
8 86.7 NA 93.2 NA 152 NA NA
9 89.1 0.9 110.5 11.2 158 18.7 12.0
10 73.5 0.8 72.0 8.9 118 37.4 1.5
11 65.3 2.3 92.6 29.6 76 35.5 5.9
12 42.4 0.9 68.3 6.3 114 29.7 3.9
Mean 69.9 1.2 120.0 8.5 179 36.4 5.6
15.6 0.5 59.0 8.0 70 11.8 3.8
Abbreviations are: VDAREA, volume of distribution; CLV, dialysis clearance; CL5, endogenous clearance; Dialysis recovery, the total amount
of drug recovered in the expended dialysate; Percent rebound, equals [((B — A)/A) x 100], where A = immediate post-dialysis plasma
concentration and B = maximum post-dialysis plasma concentration; Time to maximum rebound, time interval between the immediate
post-dialysis plasma concentration and the highest plasma concentration attained post-dialysis. Hemodialysis was performed for 2 hours (131
11 mm) using a F-80 Fresenius polysulfone membrane, QB = 417 49 and Q0 = 800 mI/mm. Results are expressed as mean SD.
a Parameters were not calculated due to the inability to maintain a peripheral intravenous access for blood sampling
In protocol 2, pharmacokinetic parameters were calculated as
follows:
VDAPP Dose/C0
T 1/2T = In 2/Ke
Where VDAPP is the apparent volume of distribution, Dose is
the dose of vancomycjn administered, and C0 is the maximal
post-distribution vancomycin concentration following the van-
comycin infusion and was calculated by back-extrapolating the
log-linear decay in the predialysis serum vancomycin concen-
trations measured prior to HFHD treatments 1 to 3 (Fig. 2).
Finally, the T "2T' or the half-life of vancomycin elimination
(that is, endogenous plus intradialytic removal) and was derived
by estimating Ke from the slope of the log-linear decay in the
predialysis serum vancomycin concentrations.
Pharmacokinetic parameters were estimated using the
RSTRIPTM program (MicroMath Scientific Software, Salt Lake
City, Utah, USA). AUC and the elimination rate constants
were calculated using the Trapezoidal Rule and nonlinear least
squares fitting, respectively. Results are presented as mean
SD.
Results
Selected pharmacokinetic parameters for the twelve patients
participating in the inpatient protocol are presented in Table 1.
Vancomycin's VDAREA was 1.2 0.5 liter/kg (range 0.6 to 2.3
liter/kg). Vancomycin clearance (CLD) with the F-SO polysul-
fone dialyzer was 120 59 mI/mm, representing a 13-fold
increase over the patient's endogenous clearance (9 8 ml!
mm). Dialysate recovery averaged 179 70 mg, indicating
removal of —17% of the body stores of vancomycin during a
single HFHD treatment.
illustrated in Figure 1 is the concentration-time curve for the
nine subjects in whom venous access was available for all
timepoints. During hemodialysis, vancomycin levels decreased
by 33% to a nadir of 9.8 2.5 g/ml. Following dialysis, a
rebound in serum vancomycin concentrations was seen in all
patients (mean 36 12%, range 19 to 60%). The post-redistri-
bution vancomycin levels were 87% of the predialysis values,
and the difference between vancomycin concentrations drawn
immediately prior to hemodialysis and values measured at peak
rebound were only 1.6 1.0 gJml. The post-dialysis redistri-
bution phase averaged six hours (Table 1), but varied among
patients (range 1 to 12 hr).
In protocol 2, 20 mg/kg of vancomycin was administered to
eight outpatients following dialysis on Monday, and pre- and
post-dialysis vancomycin levels measured during the following
three dialysis treatments. All eight participants were receiving
maintenance HFHD (Q = 438 35, Q 800 mI/mm) using
an F80 polysulfone membrane, providing a delivered Kt/V of
(Eq5)
(Eq 6)
E
8C
E
0(I,
20
15
10
5
0
0 4 8 12 26 38 50
Time, hours
Fig. 1. The impact of high-flux hemodialysis and post-dialysis redistri-
bution on serum vancomycin levels. Each concentration-time point
represents the mean SD for 9 patients.
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Patient
Weight
kg KtJV
QB Q
mI/mm
Time
mm
1 72.0 1.22 450 800 180
2 66.0 1.37 400 800 180
3 44.5 1.41 400 800 135
4 59.0 1.30 450 800 140
5 94.0 1.22 500 800 210
6 70.5 1.22 450 800 146
7 65.0 1.24 450 800 130
8 62.5 1.37 400 800 135
Mean 66.7 1.29 438 800 156
SD 13.9 0.08 35 0 29
Patients
HFH
1
D #1
2
HFHD #2
1 2
HFH
1
D #3
2 T-1/2
hr
VDAPP
liter/kgpg/ml
1 22.6 12.5 16.2 11.9 10.5 7.5 107.3 0.64
2 15.1 9.1 12.3 7.2 8.9 5.0 159.0 1.06
3 20.3 9.4 12.7 7.0 8.0 3.8 84.2 0.62
4 14.3 9.1 11.8 6.6 8.9 5.5 174.5 1.08
5 21.0 13.5 14.2 9.7 9.8 7.2 104.0 0.71
6 22.6 16.4 15.0 10.7 10.6 7.3 104.6 0.68
7 20.2 12.6 14.7 9.2 9.9 6.6 114.8 0.76
8 25.8 13.9 16.9 9.6 11.0 5.8 93.3 0.57
Mean 20.2 12.1 14.2 9.0 9.7 6.1 117.7 0.77
SD 3.6 2.5 1.7 1.8 1.0 1.2 29.8 0.18
Vancomycin (20 mg/kg i.v.) was administered over one hour follow-
ing dialysis on Monday; HFHD #1 to 3 refer to the subsequent
Wednesday, Friday, and Monday dialysis treatments, respectively.
Abbreviations are: HFHD, high-flux hemodialysis; I, plasma vancomy-
cm level drawn immediately preceding dialysis treatment; 2, plasma
vancomycin level drawn immediately following cessation of dialysis;
T-l/2, vancomycin half-life; VDAPP, apparent VD.
1.29 0.08 (Table 2). Plasma vancomycin levels preceding the
Wednesday, Friday and Monday dialysis sessions were 20.2
3.6, 14.2 1.7, and 9.7 1.0 jsg/ml, respectively (Table 3, Fig.
2). Similar to protocol 1, serum vancomycin levels declined
during each HFHD treatment (mean 38 8%, range 27 to 54%)
and the percentage reduction was comparable during each
dialysis treatment (that is, 40 8%, 37 7%, and 38 9%;
HFHD #1 to 3, respectively). Vancomycin redistribution fol-
lowing HFHD was also supported by the finding that post-
dialysis levels were typically lower than the pre-dialysis vanco-
mycin levels measured 48 hours later (Table 3, Fig. 2).
Vancomycin's half-life averaged 118 30 hours (4.9 days) and
the VDAPP was 0.77 0.18 liter/kg (Table 3).
Discussion
In protocol 1, twelve hemodialysis patients underwent a
single-dose pharmacokinetic analysis after receiving 15 mg/kg
vancomycin intravenously. During a two-hour HFHD treat-
ment (Q = 415 49; QD = 800mllmin) with a F-80 polysulfone
1 3 5 7
Time, days
Fig. 2. Illustrated are the average pre- and post-dialysis vancomycin
concentrations measured during the 7 day outpatient protocol. A
loading dose of 20 mg/kg i.v. vancomycin was administered immedi-
ately following dialysis on Monday: pre- and post-dialysis levels were
then measured during the following 3 dialysis treatments. The maximal
post-distribution vancomycin concentration following the administra-
tion of vancomycin was calculated by back-extrapolating the log-linear
decay (that is, dotted line) in the predialysis serum vancomycin
concentrations. Values and mean SD for eight patients.
membrane, vancomycin clearance increased 13-fold and serum
levels decreased by 33%, yet dialysis recovery indicated that
only 17% (179 70 mg) of vancomycin body stores were
actually removed (Table 1). Following HFHD, serum vanco-
mycin concentrations increased in all patients and the post-
"rebound" values were nearly 90% of pre-dialysis levels (Fig.
1). Thus, redistribution minimized the impact of a single HFHD
treatment on serum vancomycin concentrations.
A "rebound" in serum concentrations following extracorpo-
real therapy has been reported with a number of drugs [9—13]
and endogenous solutes, (urea, creatinine, etc.) [18—20] and is
expected whenever the rate of removal from plasma exceeds
the rate of transfer from tissue into plasma [21, 22]. During
HFHD, vancomycin elimination from the central compartment
exceeds the rate of redistribution from tissue, and blood levels
fall. Following cessation of extracorporeal therapy, blood levels
rise as vancomycin equilibrates from tissue to blood. Estimat-
ing the amount of drug removed from the percent decline in
plasma concentrations during dialysis assumes a single com-
partment model and the absence of redistribution. Neither of
these assumptions is true for vancomycin. Consequently, drug
removal estimated from the decline in plasma levels will over-
estimate dialytic clearance and supplemental dosage needs [21,
22].
The implication of this phenomena is illustrated by two recent
studies where the impact of post-dialysis redistribution on
dosing recommendations was not fully appreciated [1, 2].
Lanese, Alfrey and Molitoris reported a 50% decline in plasma
levels from pre- to immediately post-dialysis when using the
F-80 polysulfone dialyzer (Q8 = 250, Q = 500 milmin). They
concluded that as much as 50% of vancomycin body stores
(approximately 500 mg) could be removed during a four-hour
dialysis treatment and suggested administering a post-dialysis
supplement of 50% of the usual loading dose [1]. Torras et al
Table 2. Dry weight and hemodialysis prescription of the 8 patients
participating in the outpatient protocol
100
j10
I...
H H
4...
Abbreviations are: KtJV, 7 month average delivered KT/V preceding
the study; Weight, dry weight; dialysis blood flow rate; QD,
dialysate flow rate; Time, duration of dialysis treatment.
Table 3. Plasma vancomycin concentrations and derived
pharmacokinetic parameters from three consecutive outpatient
HFHD treatments performed over 7 days
HFHD #1 HFHD #2 HFHD #3
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evaluated vancomycin kinetics during a four hour dialysis (QB
= 250, QD = 500 mllmin) using a highly permeable dialyzer
composed of polyacrylonitrile (PAN) [2]. Intradialytic serum
vancomycin levels declined by 50% and from the serum vanco-
mycin concentration-time proffle, it was estimated that 34% of
vancomycin body stores were removed during each hemodial-
ysis.
Since we initiated this study, two reports have documented a
rebound in serum vancomycin levels following hemodialysis
with highly permeable membranes [23, 24]. Bohier et al found
that serum vancomycin concentrations increased to 84% of
pre-dialysis levels five hours following a 3.5 to 4 hour hemodi-
alysis (Q 219 mllmin, QD 500 mI/mm) with a F-60
polysulfone membrane (surface area = 1.2 m2) [23]. Based on
the decline in predialysis plasma vancomycin concentrations
during three successive HD treatments they concluded that
therapeutic levels (that is >5 j.z.glml) would still be present in
most patients one week after administering 1 g vancomycin (16
mg/kg) [23]. DeSoi, Sahm and Umans [24], measured vancomy-
cm clearance in five patients receiving a three to four hour
HFHD (Q = 400 to 450, QD 570 to 620 mi/mm) with three
highly permeable membranes composed of polysulfone, cellu-
lose triacetate, or polyacrylonitrile, and contrasted these results
with those obtained with a conventional cuprophane mem-
brane. A rebound (mean 19%, range 12 to 22%) in post-dialytic
serum vancomycin levels were seen during HFHD with the
three permeable membranes. These authors cautioned that
failure to appreciate post-HD redistribution might lead to inap-
propriate dosage adjustment. However, the study design did
not allow these authors to provide dosing recommendations
during HFHD [24].
To provide vancomycin dosing guidelines during HFHD, we
administered a loading dose of 20 mg/kg immediately following
dialysis on Monday: pre- and post-dialysis levels were then
measured during three consecutive dialysis treatments over
seven days (protocol 2). Participants were receiving thrice
weekly maintenance HFHD using an F80 polysullone mem-
brane (QB = 438 35 mL1min, QD = 800 mI/mm) providing a
delivered Kt/V = 1.29 0.08 (Table 2). We found that serum
vancomycin levels declined by 38% during each HFHD, a
value similar to that seen during our inpatient study (protocol 1)
and to that reported by several other investigators [1, 2, 23].
Vancomycin redistribution following HFHD was also sup-
ported by the finding that post-dialysis levels were usually
lower than the pre-dialysis vancomycin levels measured 48
hours later (Table 3, Fig. 2). Seven days after receiving a
loading dose of 20 mg/kg of vancomycin, the average pre-
HFHD vancomycin concentration was 9.7 1.0 g/ml, and all
patients had therapeutic levels (>7.5 pg/mI) [251.
Figure 2 demonstrates the average pre- and post-dialysis
vancomycin concentrations measured during the seven day
outpatient protocol. The vancomycin half-life derived from the
log-linear decline in pre-dialysis concentrations (as shown by
the dotted line) was 4.9 days (118 30 hr). This is comparable
to the endogenous hall-life measured in patients studied in
protocol 1 (131 33 hr) and reported by other investigators
[24], indicating that the contribution of dialytic clearance to
total body vancomycin removal was limited. From the elimina-
tion rate constant (Ke 2 SD) and the VDAPP derived from this
population, we have estimated the peak and trough serum
Table 4. Predicted peak and trough vancomycin serum
concentrations following a 20 mg/kg loading dose and 15 mg/kg dose
given weekly thereafter
Dose
mg/kg
Serum vancomycin
concentration p.g/ml
Peak Trough
1st Dose 20 26.0 9.2a
(14.4_5.9)b
2nd Dose 15 28.7a 10.2k
(33•925•4)b (1857)b
3rd Dose 15 29.7a l0.5a
(38•3_2S2)b (21 .2—5.7)'
4th Dose 15 30.Oa lo.6a
(4O.7_25.2)l (22.55.7)'
5th Dose 15 30.la I0.6a
(42.0—25.2)' (23.2_5.7)'
Vancomycin concentrations calculated using Ke = 6.22 x 10
1.34 x 10 hr, V = 0.77 liter/kg and a dosing interval of 7 days.
Abbreviations are: Peak, maximum post-distribution serum concentra-
tions following vancomycin infusion; Trough, predialysis serum con-
centrations 7 days following vancomycin infusion.
a Predicted average vancomycin concentration based on mean Ke
b Predicted range of vancomycin concentrations based on mean Ke
2 SD
vancomycin concentrations that would be expected following a
20 mg/kg loading dose and 15 mg/kg dose given weekly there-
after (Table 4). Considering vancomycin's broad therapeutic
window, this dosing regimen should provide therapeutic serum
vancomycin levels in the majority of patients receiving mainte-
nance HFHD under the conditions we have described.
A limitation of our study is that the pharmacokinetic analysis
was restricted to the F80 polysullone dialyzer, and that dialysis
time, QB, and QD (protocol 1), and delivered Kt/V (protocol 2),
were held constant. We chose these dialytic parameters be-
cause: (1) the blood and dialysate flow rates are typical for
HFHD and the delivered KtJV was representative of the dose of
dialysis provided to patients in our unit [15]; and (2) by favoring
vancomycin removal, it reflects the 'worst-case' scenario that
would be typically encountered clinically. Notably, Desoi et al
[24] found no difference in vancomycin kinetics when compar-
ing membranes composed of polysulfone, cellulose triacetate,
or polyacrylonitrile, indicating that dialyzer composition is not
a major determinant of vancomycin clearance during HFHD.
Most importantly, the fact that vancomycin's elimination half-
life measured in the outpatient protocol was comparable to the
endogenous (interdialytic) half-life of vancomycin in the ESRD
population (Table 1 and [24]), suggests that thrice weekly
HFHD does not alter dosing decisions. Nevertheless, it is
conceivable that with less intensive dialysis (lower QB, QD
time, or smaller dialyzer) vancomycin levels might remain
therapeutic for longer than seven days. Conversely, when the
KtJV >1.3, redosing might be required more frequently. For
this reason and because of the individual variability in vanco-
mycin dialytic clearance that we (Table 1) and others [3, 26]
have encountered, it would be prudent to obtain weekly pre-
dialysis levels (—$55per level) when patients require prolonged
therapy.
Conclusion
Although vancomycin clearance is increased during HFHD,
we have found that post-dialysis redistribution minimizes its
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impact on serum vancomycin concentrations. A 20 mg/kg i.v.
loading dose given following HFHD maintains therapeutic
vancomycin levels for at least seven days. For patients requir-
ing prolonged therapy, we recommend subsequent doses of 15
mg/kg every seven days following dialysis. This dosing sched-
ule provides a more convenient alternative to post-dialysis
dosage supplementation and reduces the likelihood of drug
accumulation and toxicity.
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